Regeneron Pharmaceuticals, Inc. (REGN) Comparison with companies in other sectors?

Regeneron Pharmaceuticals, Inc. has a share price of 106.15M. You can analyze Regeneron Pharmaceuticals, Inc. (REGN) competitors across different market sectors through stock heatmaps.

What are REGN's NET and operating margins?

Regeneron Pharmaceuticals, Inc. (REGN) operating margin is around 0.27, and net profit margin is approximately 0.32 as of the latest reports.

In what way does REGN's earnings per share (EPS) trend reflect its financial momentum?

Regeneron Pharmaceuticals, Inc. (REGN) EPS is 39.36 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Regeneron Pharmaceuticals, Inc. is 14.42, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Regeneron Pharmaceuticals, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Regeneron Pharmaceuticals, Inc. like P/E which is 13.41, P/B which is 2.05, and PEG which is 6.23. Compare them with sector averages to evaluate if the stock is priced fairly.

Regeneron Pharmaceuticals, Inc.

REGN•NASDAQ

Healthcare

Biotechnology

$567.74

$7.98(1.43%)

Fundamental Analysis of Regeneron Pharmaceuticals, Inc. (REGN)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$39.36

P/E Ratio

14.42

ROE

0.15%

Net Margin

0.32%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$60.25B

Shares OutstandingTotal number of shares issued

$106.15M

Book Value/ShareNet worth per share

$275.42

Revenue/ShareAnnual revenue per share

$132.01

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$39.36

Net MarginNet income as percentage of revenue

31.94%

Operating MarginOperating income as percentage of revenue

27.37%

ROEReturn on shareholders' equity

14.77%

ROAReturn on total assets

11.98%

ROCEReturn on capital employed

11.35%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$28.30

Cash/ShareCash and equivalents per share

$78.25

FCF YieldFree cash flow as percentage of market cap

5.02%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$1.76

Dividend YieldAnnual dividend as percentage of stock price

0.31%

Financial Ratios Analysis data is not available for REGNFinancial Ratios Analysis details for REGN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for REGNSector Benchmarking details for REGN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Regeneron Pharmaceuticals, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Regeneron Pharmaceuticals, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Regeneron Pharmaceuticals, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Regeneron Pharmaceuticals, Inc.

For Regeneron Pharmaceuticals, Inc., essential financial indicators include EPS 39.36, PE 14.42, and ROE 0.15. These key ratios reveal insights into Regeneron Pharmaceuticals, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Regeneron Pharmaceuticals, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Regeneron Pharmaceuticals, Inc.

Metrics like Net Margin 31.94% and ROA 11.98% shed light on how well Regeneron Pharmaceuticals, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Regeneron Pharmaceuticals, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Regeneron Pharmaceuticals, Inc.

Using ratios such as P/B Ratio 2.05 and PEG Ratio 6.23, investors can assess whether Regeneron Pharmaceuticals, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Regeneron Pharmaceuticals, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Regeneron Pharmaceuticals, Inc.

Financial health indicators, such as Debt/Equity Ratio 0.09 and Cash Flow $28.30, provide a snapshot of Regeneron Pharmaceuticals, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Regeneron Pharmaceuticals, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Regeneron Pharmaceuticals, Inc.

Investing in Regeneron Pharmaceuticals, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Regeneron Pharmaceuticals, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;